longer disease duration (0.96; 0.94, 0.98) and worse HAQ (0.74; 0.60, 0.92). Social functioning improved with better VASQOL (8.62; 3.32, 13.91), but worsened with more comorbidities (−0.92; −1.49, −0.35), anxiolytic and/or antidepressant use (−5.33; −7.68, −2.98), worse RADAI (−1.54; −2.80, −0.28), HAQ (−8.38; −10.51, −6.25) and fatigue (−1.06; −1.48, −0.65). Furthermore, the mechanism by which RADAI affected social functioning did not appear to be through pain (0.20; −0.43, 0.84), but through HAQ as it absorbed 56% of the explanatory power of RADAI. CONCLUSIONS: Performance of social roles was limited among RA patients with more HAQ disability, and improved by better quality of life. Disease activity appeared to infl uence social functioning through worse physical disability but not through pain.
1
BioEPI, Clinical and Translational Research Center, Oeiras, Portugal; 2 University of Nebraska Medical Center, Omaha, NE, USA; 3 National Databank for Rheumatic Diseases, Wichita, KS, USA BACKGROUND: Disease activity and disability should be assesssed at each rheumatoid arthritis (RA) patient visit to monitor response to therapy. Disease activity has been traditionally evaluated by the disease activity scale (DAS-28) and the ACR criteria, which depend on physicians, but few studies have analyzed short-term predictors of the patient self-reported RA disease activity index-RADAI. Disability is routinely assessed by the health assessment questionnaire (HAQ) whose long term predictors, but not short-term, have been extensively studied. OBJECTIVES: To analyze whether the 6-month baseline levels of HAQ and of RADAI and other factors predict change at 6-month intervals. METHODS: RA patients from the biannual NDB-Portugal cohort were used. For each patient, differences between two consecutive 6-month intervals were computed for HAQ (0-3, 3 is worse) and RADAI (0-10, 10 is worse). For each scale, a binary outcome was constructed based upon these differences, where a positive increment meant worsening in function and disease activity. Patients' observations whose increments were null were excluded. Univariate (UV) and multivariate (MV) generalized estimating equations were used. Factors included age, sex, marital status, disease duration, education level, number of major comorbidities, paid work status and 6-month baseline HAQ and RADAI levels. RESULTS: MV analyses revealed that the main predictors of HAQ were baseline HAQ: (OR: 0.49, 95% CI 0.44, 0.54), number of comorbidities (1.09 (1.05, 1.14)), and age (1.02 (1.01, 1.02)); For RADAI they were, baseline RADAI (0.69 (0.66, 0.73)), comborbidities (1.11 (1.07, 1.16)), and educational level (0.95 (0.93, 0.97)). CONCLUSIONS: Worse baseline levels of HAQ and RADAI predicted their respective improvement 6-months later. This could be due to optimization of treatment strategies when worse baseline scores are detected, but whatever the reason, performing these two patient reported outcomes are a quick and non-rheumatologist dependent way to improve patients' disease status over 6-month intervals.
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USE OF PATIENT-REPORTED OUTCOMES IN ON-LINE COMMUNITIES TO CONDUCT OBSERVATIONAL COMPARATIVE EFFECTIVENESS RESEARCH: A PILOT STUDY IN RHEUMATOID ARTHRITIS
Cascade E 1 , Bharmal M 2 1 iGuard, Rockville, MD, USA; 2 Quintiles, Rockville, MD, USA OBJECTIVES: The demand for comparative effectiveness research (CER) data from payers, physicians, and patients is signifi cant, but the cost and time associated with prospective randomized trials is a barrier to rapid decision-making. Use of patientreported outcomes (PROs) collected via on-line patient communities provides one channel for rapid data collection, particularly in conditions such as rheumatoid arthritis (RA), where validated PRO instruments are available. METHODS: A random sample of iGuard.org members in the US treated with non-steroidal anti-infl ammatory drug (NSAIDs), oral disease-modifying antirheumatic drugs (DMARDs), or biologics for RA completed the Rheumatoid Arthritis Disease Activity Index (RADAI) and a series of other questions related to their disease. iGuard.org is a free medication monitoring service that is introduced to patients through multiple sources including physician, pharmacy and online referrals. For this study, we report pilot baseline data on patientreported RADAI, pain, and joint counts across the three treatment groups to demonstrate use of on-line communities in supporting CER. RESULTS: A total of 153 RA patients completed the study: 49 treated with NSAIDs only, 51 exposed to oral DMARDs, and 53 exposed to biologics. The mean (SD) RADAI score was 4.59 (2.16). Adjusting for age and gender and multiple comparisons, there were signifi cant differences between the three treatment groups on RADAI scores (p = 0.0045) and patient global assessment of pain (p = 0.0357) but not on the number of painful joints (p = 0.3512). The trend was towards patients on NSAIDs only having worse outcomes compared to patients on biologics or patients on oral DMARDs. CONCLUSIONS: This pilot study demonstrates the possibility of collecting baseline disease severity data directly from patients using the RADAI, which is sensitive to detect differences by treatment modality. The next step in the pilot program will be to investigate the potential for capturing longitudinal disease progress information amongst patients in on-line communities.
RESPIRATORY-RELATED DISORDERS -Clinical Outcomes Studies
PRS1 RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS
Paes BA 1 , Li A 2 , Lanctot KL 2 , Mitchell I 3 1 McMaster University, Hamilton, ON, Canada; 2 Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 3 University of Calgary, Calgary, AB, Canada OBJECTIVES: To examine the pattern of palivizumab utilization and compliance in infants with pre-existing disease within the Canadian Registry Database (CARESS). METHODS: A prospective, registry of infants across 27 sites who received at least 1 dose of palivizumab during the 2006-2009 RSV seasons. Neonatal and demographic data were collected from the parent/caregiver at enrollment. Data on palivizumab utilization, compliance, and outcomes related to respiratory illness (RI) events were collected monthly. Premature infants ≤35 completed weeks gestational age without medical conditions who met standard approval criteria for palivizumab (Group 1) were compared to those with underlying medical disorders who received prophylaxis (Group 2). RESULTS: Group 1 (n = 3379) Group 2 (n = 489). Male: 56.8% versus 54.6% (P = 0.433). Average Enrollment Age (months) ± SD: 3.6 ± 3.4 versus 9.9 ± 8.8 (P = 0.000). Average GA (weeks) Mean ± SD: 31.0 ± 3.1 versus 37.1 ± 4.3 (P = 0.000). Average # injections ± SD: 3.6 ± 1.5 versus 3.7 ± 1.5 (P = 0.159). Hospitalization Rate (HR) for RI: 4.1% versus 9.2% (P = 0.000). RSV HR: 1.3% versus 2.7% (P < 0.05). On average infants received 86.0% ± 28.3% of the expected number of injections. Group 2 infants comprised Down syndrome (n = 118, 24.1%), upper airway anomalies (n = 112, 22.9%), cystic fi brosis (n = 62, 12.7%), neuromuscular impairment (n = 42, 8.6%), pulmonary (n = 38, 7.8%), multiple system disorders (n = 34, 7.0%), cardiac (n = 17, 3.5%), immunocompromise (n = 8, 1.6%), and miscellaneous (n = 58, 11.9%). From 2006-2009, the proportion of Group 2 infants receiving prophylaxis increased 2-fold from 5.6% (69/1224) to12.2% (245/2016). Overall. Group 2 infants were older at enrollment with more advanced GA and had significantly higher RI and RSV hospitalization rates. No serious adverse events directly related to palivizumab occurred. CONCLUSIONS: Results imply that infants with underlying medical disorders that are not approved for prophylaxis by advisory bodies and current position statements are at greater risk for RSV infections and hospitalization.
PRS2
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2006-2009)
Paes BA 1 , Li A 2 , Lanctot KL 2 , Mitchell I 3 1 McMaster University, Hamilton, ON, Canada; 2 Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 3 University of Calgary, Calgary, AB, Canada OBJECTIVES: Palivizumab is used for respiratory syncytial virus (RSV) prophylaxis in high risk children. Data on seasonality, risk factors, and outcomes are necessary to evaluate the impact of palivizumab on the incidence of RSV infections, minimize health care resources and identify which infant sub-sets are receiving prophylaxis.To determine current usage of palivizumab prophylaxis, compliance patterns, hospitalization rate (HR) and outcomes in children at high-risk of respiratory syncytial virus (RSV) infection through a Canadian Registry Database (CARESS). METHODS: A prospective, study of infants who received at least 1 dose of palivizumab in the 2006-2009 RSV seasons across 27 sites. Neonatal and demographic data were collected upon enrolment. Parents/caregivers were contacted monthly for data on palivizumab utilization, compliance and outcomes related to any respiratory tract events. RESULTS: A total of 4926 infants aged 2 days-47 months (mean = 5.4 months) were enrolled. Participants were typically male (57.1%) and Caucasian (70.8%). Gestational age (GA) was 32.2 ± 4.6 completed weeks. 3480 (70.6%) premature infants received palivizumab (≤35 completed weeks GA), 403 (8.2%) required O2, 471 (9.6%) had congenital heart disease and 572 (11.6%) were prophylaxed for other risk factors. On average patients received 3.7 ± 1.5 injections, with 17,982 doses given overall. There were no drug related serious adverse events.296 infants required 357 hospitalizations for respiratory tract infections with a hospitalization rate of 6.0%. There were significant differences between indications for palivizumab (chi-square = 71.8, P < 0.005). The overall RSV positive HR was 1.38%. Hospitalization rates were highest in infants of aboriginal descent (15.0%, chi-square = 22.2, P < 0.005). Hospitalized infants had a lower percentage of compliant injections (62.8% versus 68.6%, p = 0.003). CON-CLUSIONS: The RSV HR in the 2006-2009 RSV seasons resembled several published reports (range 1.3%-5.3%). RSV HR may be decreasing because of compliance with palivizumab prophylaxis, variability in RSV epidemiology, hospital admission criteria and preventive education.
PRS3 COMORBIDITY PROFILING OF COPD PATIENTS IN THE UNITED KINGDOM PRIMARY CARE USING AN INCIDENCE BASED APPROACH TO DETECT ASSOCIATIONS WITH THE DISEASE
Kiri VA PAREXEL International, Uxbridge, London, UK OBJECTIVES: Comorbidity is an important factor in any comparative assessment of treatments associated with morbidity and mortality of patients. Many factor such as age, gender and duration of a disease can infl uence the impact of comorbid diseases on quality of life. In the health care setting (the primary source of data for most observational studies), the decision to give a particular treatment to a particular patient with a given disease is generally based on patient specifi c characteristics, the most important of which is disease condition. Thus, confounding by indication/disease
